Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02463253 · ClinicalTrials.gov registry record
Correlation of Molecular Biomarkers With Biopsy Findings and Outcomes in Renal Transplant Recipients
A clinical trial, sponsored by University of California, Davis.
- Completed
- Registry status
- 20
- Enrollment target
NCT02463253 is a clinical trial that has completed, run by University of California, Davis. The registered enrollment target is 20 participants.
The verdict
NCT02463253 has completed, sponsored by University of California, Davis.
- COMPLETED
- Registry status
- 20 participants
- Enrollment target
Study Summary
This is a single-center, prospective, non-randomized, observational study to evaluate specific proteogenomic biomarker panels for acute rejection (AR) and chronic allograft nephropathy/interstitial fibrosis and tubular atrophy (CAN/IFTA) in blood, urine and kidney tissue (biopsy) in kidney transplant recipients. Proteogenomic profiles will be routinely monitored over one year after enrollment.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02463253
The ClinicalTrials.gov registry entry for NCT02463253 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Davis, which has 657 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT02463253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02463253 about?
NCT02463253 is a clinical study titled "Correlation of Molecular Biomarkers With Biopsy Findings and Outcomes in Renal Transplant Recipients". This is a single-center, prospective, non-randomized, observational study to evaluate specific proteogenomic biomarker panels for acute rejection (AR) and chronic allograft nephropathy/interstitial fibrosis and tubular atrophy (CAN/IFTA) in blood, urine and kidney tissue (biopsy) in kidney transplan...
What is the current status of trial NCT02463253?
This trial is currently completed. The enrollment target is 20 participants. The study started on 2015-04. Estimated completion is 2016-05.
Who is sponsoring clinical trial NCT02463253?
This trial is sponsored by University of California, Davis, which has 657 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.